

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Almstead Neil Gregory</u>  (Last) (First) (Middle) C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT  (Street) SOUTH PLAINFIELD NJ 07080  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>PTC THERAPEUTICS, INC. [ PTCT ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP Research Pharma Ops &amp; Tech</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/19/2018</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/19/2018		M <sup>(1)</sup>		20,000	A	\$10.85	37,154	D	
Common Stock	06/19/2018		S <sup>(1)</sup>		8,000	D	\$48.09 <sup>(2)</sup>	29,154	D	
Common Stock	06/19/2018		S <sup>(1)</sup>		12,000	D	\$48.46 <sup>(3)</sup>	17,154	D	
Common Stock								5,125	I	By spouse

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right To Buy)	\$10.85	06/19/2018		M <sup>(1)</sup>			20,000	(4)	05/15/2023	Common Stock	20,000	\$10.85	46,898	D	
Stock Option (Right To Buy)	\$451.2							(4)	05/15/2019	Common Stock	200		200	D	
Stock Option (Right To Buy)	\$1,149.6							(4)	02/02/2020	Common Stock	200		200	D	
Stock Option (Right To Buy)	\$490.8							(4)	04/27/2021	Common Stock	216		216	D	
Stock Option (Right To Buy)	\$218.4							(4)	01/10/2022	Common Stock	166		166	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right To Buy)	\$10.85							(4)	05/15/2023	Common Stock	3,102		3,102	D	
Stock Option (Right To Buy)	\$27.05							(4)	01/27/2024	Common Stock	40,000		40,000	D	
Stock Option (Right To Buy)	\$51							(5)	01/01/2025	Common Stock	69,550		69,550	D	
Stock Option (Right To Buy)	\$30.86							(6)	01/03/2026	Common Stock	55,000		55,000	D	
Stock Option (Right To Buy)	\$11.23							(7)	01/02/2027	Common Stock	35,000		35,000	D	
Stock Option (Right To Buy)	\$18.01							(8)	01/02/2028	Common Stock	70,000		70,000	D	
Stock Option (Right To Buy)	\$508.8							(4)	10/07/2019	Common Stock	12		12	I	By spouse
Stock Option (Right To Buy)	\$1,149.6							(4)	02/02/2020	Common Stock	1		1	I	By spouse
Stock Option (Right To Buy)	\$490.8							(4)	04/27/2021	Common Stock	7		7	I	By spouse
Stock Option (Right To Buy)	\$218.4							(4)	01/10/2022	Common Stock	7		7	I	By spouse
Stock Option (Right To Buy)	\$27.05							(4)	01/27/2024	Common Stock	1,300		1,300	I	By spouse
Stock Option (Right To Buy)	\$51							(5)	01/01/2025	Common Stock	2,060		2,060	I	By spouse

**Explanation of Responses:**

- The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$47.58 to \$48.37 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from \$48.38 to \$48.81 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Currently exercisable.
- This option was granted on January 2, 2015, and vests over four years, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
- This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
- This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.
- This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

**Remarks:**

/s/ Avraham S. Adler, attorney-  
in-fact 06/21/2018

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**